Table 2 Time-to-recurrence in Breast Conserving patients in GM. Adjusted hazard ratios (HR) and associated 95% confidence intervals (1982 patients entered in the analysis to exclude missing cases.

Variable	Multivariate LR HR	p	Multivariate DR HR	p
Margin Clear>2 mm	REF		REF
Close 1.1–2 mm	0.98 (0.42–2.27)	0.963	1.45 (0.72–2.95)	0.302
Involved Margin ≤1 mm	2.16 (1.31–3.58)	0.003	1.73 (1.03–2.88)	0.037
Age at Diagnosis	0.99 (0.97–1.01)	0.156	0.99 (0.97–1.01)	0.416
Radiotherapy	0.50 (0.24–1.00)	0.061	0.50 (0.25–0.99)	0.048
Chemotherapy	0.70 (0.34–1.46)	0.338	0.59 (0.30–1.17)	0.132
Hormone therapy	0.35 (0.13–0.96)	0.040	0.25 (0.10–0.63)	0.003
Herceptin therapy	3.69 (0.59–23.14)	0.163	0.67 (0.11–3.87)	0.649
Symptomatic vs. screening	1.94 (1.00–3.74)	0.049	1.59 (0.79–3.17)	0.191
ER Positive	3.58 (1.19–10.78)	0.023	2.56 (0.91–7.23)	0.076
PR Positive	0.39 (0.18–0.62)	<0.001	0.69 (0.37–1.28)	0.235
HER2 Positive	0.21 (0.03–1.42)	0.109	1.15 (0.21–6.26)	0.871
T-Stage 1 (0–2 cm)	REF		REF
T-Stage 2 (2.1cm-5cm)	2.32 (1.08–4.97)	0.031	1.69 (0.82–3.52)	0.158
T-Stage 3 ( > 5 cm)	2.81 (0.32–24.31)	0.349	0.76 (0.09–6.37)	0.804
No. of nodes
Negative (0)	REF		REF
1–3	1.34 (0.73–2.48)	0.349	2.62 (1.47–4.66)	0.001
4–9	0.93 (0.27–3.19)	0.912	5.26 (2.45–11.29)	<0.001
10+	0.78 (0.17–3.63)	0.753	2.77 (0.95–8.07)	0.062
Size (mm)	0.98 (0.94–1.03)	0.420	1.027 (0.99–1.07)	0.169
Tumour Grade 1	REF		REF
Tumour Grade 2	1.42 (0.63–3.21)	0.398	4.28 (0.99–18.59)	0.052
Tumour Grade 3	1.71 (0.66–4.34)	0.266	8.71 (1.91–39.62)	0.005
Lymphovascular invasion	1.66 (0.94–2.94)	0.080	1.09 (0.62–1.90)	0.776

Median time to DR for involved margins was 33.8 months and 42.0 months for LR.
Bold values represent the analyses that produced a clinically and statistically significant finding.
All variables shown above were entered into the multivariate.
NB: site of treatment has been hidden as it did not affect time to recurrence and was not significant.
Additional data excluding TOI was performed and is shown in Supplementary Tables 7, 8.

Search